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Liraglutide prevents metabolic side-effects and improves recognition and
working memory during antipsychotic treatment in rats
Abstract
BACKGROUND: Antipsychotic drugs (APDs), olanzapine and clozapine, do not effectively address the
cognitive symptoms of schizophrenia and can cause serious metabolic side-effects. Liraglutide is a synthetic
glucagon-like peptide-1 (GLP-1) receptor agonist with anti-obesity and neuroprotective properties. The aim
of this study was to examine whether liraglutide prevents weight gain/hyperglycaemia side-effects and
cognitive deficits when co-administered from the commencement of olanzapine and clozapine treatment.
METHODS: Rats were administered olanzapine (2 mg/kg, three times daily (t.i.d.)), clozapine (12 mg/kg,
t.i.d.), liraglutide (0.2 mg/kg, twice daily (b.i.d.)), olanzapine + liraglutide co-treatment, clozapine +
liraglutide co-treatment or vehicle (Control) ( n = 12/group, 6 weeks). Recognition and working memory
were examined using Novel Object Recognition (NOR) and T-Maze tests. Body weight, food intake,
adiposity, locomotor activity and glucose tolerance were examined. RESULTS: Liraglutide co-treatment
prevented olanzapine- and clozapine-induced reductions in the NOR test discrimination ratio ( p < 0.001).
Olanzapine, but not clozapine, reduced correct entries in the T-Maze test ( p < 0.05 versus Control) while
liraglutide prevented this deficit. Liraglutide reduced olanzapine-induced weight gain and adiposity.
Olanzapine significantly decreased voluntary locomotor activity and liraglutide co-treatment partially
reversed this effect. Liraglutide improved clozapine-induced glucose intolerance. CONCLUSION:
Liraglutide co-treatment improved aspects of cognition, prevented obesity side-effects of olanzapine, and the
hyperglycaemia caused by clozapine, when administered from the start of APD treatment. The results
demonstrate a potential treatment for individuals at a high risk of experiencing adverse effects of APDs
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Abstract:     28 
Background: Antipsychotic drugs (APDs), olanzapine and clozapine, do not effectively 29 
address the cognitive symptoms of schizophrenia and can cause serious metabolic side-30 
effects. Liraglutide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist with anti-31 
obesity and neuroprotective properties. Aim: To examine whether liraglutide prevents weight 32 
gain/hyperglycaemia side-effects and cognitive deficits when co-administered from the 33 
commencement of olanzapine and clozapine. Methods: Rats were administered olanzapine 34 
(2mg/kg, t.i.d.), clozapine (12mg/kg, t.i.d.), liraglutide (0.2mg/kg, b.i.d.), 35 
olanzapine+liraglutide co-treatment, clozapine+liraglutide co-treatment or vehicle (control) 36 
(n=12/group, 6 weeks). Recognition and working memory were examined using Novel 37 
Object Recognition (NOR) and T-maze tests. Body weight, food intake, adiposity, locomotor 38 
activity and glucose tolerance were examined. Results: Liraglutide co-treatment prevented 39 
olanzapine- and clozapine-induced reductions in the NOR test discrimination ratio (p<0.001). 40 
Olanzapine, but not clozapine, reduced correct entries in the T-maze test (p<0.05 vs control) 41 
while liraglutide prevented this deficit. Liraglutide reduced olanzapine-induced weight gain 42 
and adiposity. Olanzapine significantly decreased voluntary locomotor activity and liraglutide 43 
co-treatment partially reversed this effect. Liraglutide improved clozapine-induced glucose 44 
intolerance. Conclusion: Liraglutide co-treatment improved aspects of cognition, prevented 45 
obesity side-effects of olanzapine, and the hyperglycaemia caused by clozapine, when 46 
administered from the start of APD treatment. The results demonstrate a potential treatment 47 
for individuals at a high risk of experiencing adverse effects of APDs.  48 
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1. Introduction  52 
Cognitive impairment, including deficits in recognition and working memory, affects 80% of 53 
people with schizophrenia (2006; Lee and Park, 2005; Pelletier et al., 2005). Cognition is 54 
recognised as a core component of the disorder from which other symptom domains (positive 55 
and negative symptoms) arise (Kahn and Keefe, 2013) and can be a predictor of functional 56 
outcome (Lepage et al., 2014). Despite the importance and prevalence of cognitive deficits, 57 
antipsychotic drugs (APDs) are limited in their ability to treat this symptom domain. For 58 
example, the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and other 59 
studies have reported minimal or no overall effect of olanzapine, clozapine, risperidone, 60 
ziprasidone, perphenazine or quetiapine fumarate on cognition (Keefe et al., 2007; Nielsen et 61 
al., 2015). In fact, several authors argue that APDs may worsen cognition, particularly typical 62 
1st generation APDs (Woodward et al., 2007; Kasper and Resinger, 2003). Similar findings 63 
have been reported in rodent studies, with either no effect (Kamei et al., 2006), or impaired 64 
working and recognition memory following olanzapine and clozapine administration (Levin 65 
et al., 2005; Castro et al., 2007; Addy and Levin, 2002; Levin and Christopher, 2006; Ortega-66 
Alvaro et al., 2006). On the contrary, olanzapine, clozapine and ziprasidone attenuate 67 
cognitive deficits following phencyclidine and MK-801 treatment in rodents (Abdul-Monim 68 
et al., 2006; Karasawa et al., 2008).  69 
 70 
Atypical (2nd generation) APDs (particularly olanzapine and clozapine) can also cause weight 71 
gain and hyperglycaemia side-effects that can lead to obesity and Type 2 diabetes mellitus 72 
(T2DM), as well as poor medication compliance (Weston-Green et al., 2013; Das et al., 2012; 73 
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Leucht et al., 2009). Furthermore, T2DM and obesity can exacerbate cognitive impairment in 74 
schizophrenia patients (Han et al., 2013; Lindenmayer et al., 2012). Overall, novel 75 
therapeutic approaches for the treatment of cognitive impairment in schizophrenia and the 76 
prevention of metabolic side-effects associated with current medications are required. 77 
 78 
Synthetic analogues of the incretin hormone glucagon-like peptide-1 (GLP-1), such as 79 
liraglutide and exenatide, can attenuate hyperglycaemia in T2DM and reduce diabetes-80 
associated weight gain (Garber et al., 2011; Robinson et al., 2013; de Wit et al., 2014). 81 
Several studies suggest that liraglutide can improve metabolic parameters during APD 82 
treatment. For example, a liraglutide increased glucose tolerance and reduced body weight 83 
during a recent clinical trial of overweight pre-diabetic individuals schizophrenia spectrum 84 
disorder treated with olanzapine or clozapine (Larsen et al., 2017). Liraglutide also induced 85 
weight loss and restored glucose homeostasis in an earlier case study of a schizophrenia 86 
patient treated with clozapine (Ishøy et al., 2014), and in rats with established obesity and 87 
T2DM caused by chronic olanzapine administration (Lykkegaard et al., 2008). Therefore, 88 
there is evidence to suggest that liraglutide can treat established metabolic side-effects of 89 
olanzapine and clozapine; however, it is unclear whether liraglutide can prevent the onset of 90 
weight gain and glucose imbalance when combined with APDs from the start of treatment. In 91 
addition to its metabolic benefits, the GLP-1 signalling system in the brain plays an important 92 
role in learning, memory and neuroprotection (see reviews by Holscher, 2013; Holst et al., 93 
2011). Endogenous GLP-1 is expressed in the nucleus of the solitary tract (NST) that project 94 
throughout the brain (Hamilton and Holscher, 2009). Exogenous glucagon-like peptide-1 95 
receptor (GLP-1R) agonists, liraglutide, lixisenatide and exendin-4, can exert central effects 96 
by rapidly crossing the blood brain barrier (Hunter and Holscher, 2012; Kastin and 97 
Akerstrom, 2003). GLP-1Rs are widely expressed in the brain, including regions associated 98 
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with cognitive function such as the hippocampus, amygdala, prefrontal cortex and nucleus 99 
accumbens (Katsurada and Yada, 2016; Hamilton and Holscher, 2009; Larsen and Holst, 100 
2005; Merchenthaler et al., 1999). Interestingly, GLP-1-R knockout mice exhibit impaired 101 
recognition and spatial memory during the novel object recognition (NOR) and Morris water 102 
maze tests, as well as reduced long-term potentiation in the hippocampal CA1 region, 103 
compared to wild-type littermates (Abbas et al., 2009). Conversely, hippocampal GLP-1R 104 
overexpression improves memory and learning (During et al., 2003). Liraglutide prevents 105 
memory impairments, preserves synapses and synaptic plasticity, while exenatide improves 106 
short and long-term memory and spatial learning in mouse models of Alzheimer’s disease 107 
(McClean et al., 2011; Bomba et al., 2013). However, whether liraglutide can improve 108 
cognition when administered from the start of APD treatment is unknown. The aim of this 109 
study was to investigate 1) the effect of liraglutide co-treatment on learning, working and 110 
recognition memory, and 2) the ability of liraglutide to prevent metabolic side-effects, in rats 111 
commencing olanzapine or clozapine treatment.  112 
 113 
2. Methods 114 
2.1 Ethics Statement 115 
This study is reported in accordance with the Animal Research: Reporting of In Vivo 116 
Experiments (ARRIVE) guidelines (Kilkenny et al., 2010). The completed ‘ARRIVE 117 
Guidelines Checklist’ is included in the Supplementary Information (Supplementary Figure 118 
S1). All experimental procedures were approved by the Animal Ethics Committee, University 119 
of Wollongong, Australia (AE14/30), and complied with the Australian Code of Practice for 120 
the Care and Use of Animals for Scientific Purposes (NHMRC, 2013). Every effort was made 121 
to minimize the number of animals and their suffering in this study.  122 
 123 
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2.2 Animals and treatment 124 
Female Sprague-Dawley rats (200 – 220 g, Animal Resource Centre, Perth, WA, Australia) 125 
(n=72) were individually housed on corn cob bedding, with plastic tunnels and nesting 126 
material for environmental enrichment. The housing environment was set to 22 °C with a 127 
reverse light-dark cycle (photophase 1900-0700 h) so that behavioural experiments were 128 
conducted during the normal nocturnal active period of rats. Ad libitum access to water and 129 
standard laboratory chow (3.9 kcal/g; fat 10%, carbohydrates 74% and protein 16%) was 130 
provided throughout the study unless otherwise stated. An initial one-week environmental 131 
habituation period was followed by a training week where rats learnt to self-administer 132 
cookie dough pellets offered by researchers on a metal spatula, as previously described 133 
(Weston-Green et al., 2011). Rats were randomised into six treatment groups: 0.2 mg/kg 134 
liraglutide (Victoza, Novo Nordisk, Bagsværd, Denmark) (subcutaneous (SC) injection + oral 135 
cookie dough pellet without drug), 2 mg/kg olanzapine (Zyprexa, Eli Lilly, Indianapolis, IN, 136 
USA) (oral cookie dough pellet + sterile water SC), 12 mg/kg clozapine (Clozaril, Norvatis, 137 
Basel, Switzerland) (oral cookie dough pellet + sterile water SC), olanzapine+liraglutide co-138 
treatment, clozapine+liraglutide co-treatment, or vehicle (oral cookie dough pellet without 139 
drug + sterile water (SC)) (n=12). Drug preparation was performed as detailed in Weston-140 
Green et al (2011). Briefly, de-coated olanzapine and clozapine tablets were pulverized and 141 
the assigned doses were added to a dry cookie-dough mix. Immediately prior to 142 
administration, water was added to achieve a dry-dough consistency and rats were 143 
administered a 0.3 g cookie-dough pellet. Treatments were administered for six weeks 144 
(Figure 1A). Clinical administration routes were utilised, and clinical doses were converted to 145 
rat equivalents using body surface area calculations (Reagan-Shaw et al., 2008) and based on 146 
previous reports (Sturis et al., 2003; Weston-Green et al., 2011). APDs were administered 147 
three times daily (t.i.d) at 8-hourly intervals (0700, 1500 and 2300 h), while liraglutide was 148 
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administered twice daily (b.i.d) (0700 and 1500 h), based on the pharmacokinetic half-life of 149 
these drugs in the rat (Aravagiri et al., 1999; Baldessarini et al., 1993; Sturis et al., 2003). 150 
Cookie dough preparation and administration were conducted as we have previously 151 
described (Weston-Green et al., 2011). Body weight, food and water intake were measured 152 
weekly. Food intake was measured by weighing the amount of chow remaining in the hopper, 153 
including any chow dispersed throughout the cage floor. 154 
 155 
2.3 Oral Glucose Tolerance Test (OGTT) 156 
An OGTT was performed during week 2 of treatment. Rats were fasted overnight then fasting 157 
(baseline, time 0) blood glucose levels were measured using samples obtained from the 158 
lateral tail vein. Measurements were obtained using a handheld glucometer (Accu-Chek 159 
Performa Blood Glucose Meter, Sydney, Australia) in triplicate. Rats then received an oral 160 
bolus of 2 g/kg glucose and blood sampling was repeated at 30 minute intervals until 180 161 
mins after glucose administration. The mean blood glucose area under the curve (AUC) 162 
OGTT blood glucose concentration was calculated using the trapezoidal method, as 163 
previously described (Purves, 1992). Treatment groups were alternated throughout the testing 164 
period. 165 
 166 
2.4 Behavioural Testing 167 
Behavioural testing was performed during weeks 3-5 of treatment to assess 24-hour voluntary 168 
locomotor activity, memory and learning. Testing was conducted during the active dark phase 169 
(0900-1400 hours) with minimal white light interference and a 24-hour rest period between 170 
tests to minimise animal stress. Rats were tested from alternating treatment groups 171 
throughout the testing period. Rat behaviour was recorded using standard commercial 172 
cameras (Logitech Pty Ltd, NSW Australia) and recordings were de-identified. Equipment 173 
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was cleaned between trials to eliminate olfactory cues. To further minimise animal stress, 174 
behavioural tests were performed in order of invasiveness, as listed below.  175 
 176 
2.4.1 Voluntary Locomotor Activity 177 
Voluntary locomotor activity was measured using a rodent activity wheel with an integrated 178 
living chamber apparatus (Activity Wheel and Living Chamber, Model 80859, Lafayette 179 
Instrument Company, IN, USA). Rats were placed in clean cages equipped with freely 180 
spinning running wheels that were open to allow the rat a choice to either engage in voluntary 181 
locomotion or to reside in the living chamber (containing corncob bedding and free access to 182 
food and water) for 24-hours. Distance travelled (m) and velocity (m/sec) in the running 183 
wheel were determined using an infra-red sensor counter attached to a USB Computer 184 
Interface and quantified using Activity Wheel Monitor Software (Lafayette Instrument 185 
Company, IN, USA). 186 
 187 
2.4.2 Novel Object Recognition (NOR) Test  188 
The NOR test was employed to assess recognition memory, as demonstrated by the ability of 189 
a rat to distinguish between novel and familiar objects. The NOR test is driven by the rat’s 190 
innate preference towards novelty (Cheng et al., 2014). Testing was conducted based on the 191 
protocol by Bevins and Besheer (2006) and our previous report (Osborne et al., 2017). 192 
Briefly, rats were provided with two objects (plastic building blocks) in their home cage for 193 
24 hour familiarisation prior to the testing day. During the first (familiarisation) trial, each rat 194 
was placed in a dimly lit (even lighting of 25 lux) open arena (60 cm x 60 cm x 60 cm, black 195 
matte) with the two familiar objects positioned equidistant from the rat (Figure 1B). The two 196 
familiar objects were positioned in the upper half of the arena, while the rat was positioned in 197 
the lower half of the arena with head pointed towards the centre of the wall, away from the 198 
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objects (Figure 1B). The rat was allowed to explore the arena for 10 minutes then returned to 199 
its home cage for 1 hour. During the second (test) trial, one familiar object was replaced with 200 
a novel object (a toy figurine) in the arena (Figure 1B). The rat was returned to the arena and 201 
allowed to explore for 3 minutes. Object interaction time was recorded, defined as time spent 202 
nosing, sniffing, licking or touching the objects with forepaws. Inadvertent contact (rearing 203 
over object to explore other parts of the arena, bumping object in passing) were not included 204 
as object interaction, as described by Bevins and Besheer (2006). A discrimination ratio was 205 
calculated for each rat using TN / TTOT (TN = novel object exploration time, TTOT = total object 206 
exploration time (sec)), as previously described (Bevins and Besheer, 2006; Osborne et al., 207 
2017). A discrimination ratio score of 1 indicated a preference for the novel object, whereas a 208 
score closer to 0 indicated a greater preference for the familiar object. 209 
 210 
2.4.3 Rewarded T-maze Alternation Test 211 
The T-maze alternation test was used to assess working memory based on the method 212 
described by Deacon and Rawlins (2006) and our previous report (Osborne et al., 2017). The 213 
maze consisted of a matte black ‘T’-shaped arena (50 cm long x 10 cm wide, with 30 cm high 214 
walls) with removable dividers to allow access to the left and right goal arms of the upper 215 
part of the maze (Figure 1C). A 10cm central partition distal to the start arm was utilised to 216 
limit rat access to one goal arm of the T-maze at a time and improve alternation rate (Deacon 217 
and Rawlins, 2006). The maze was positioned at ground level and exposed to an even low 218 
light level of 20 lux. Rats were familiarised with a chocolate pellet reward stimulus in their 219 
home cages 24-hours prior to testing. Food was then restricted to 5 g / 100 g body weight of 220 
rat (approximately 40% of the normal intake) overnight prior to the habituation, training and 221 
testing days. During the habituation trial, the reward stimulus was placed in both open arms 222 
of the maze. A rat was placed in the start arm of the arena and allowed to freely explore the 223 
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maze for 10 minutes, then returned to its home cage. All rats were successfully habituated 224 
during this habituation trial as the reward stimulus was consumed from both arms of the T-225 
maze (Deacon and Rawlins, 2006). Rats then underwent two consecutive days of training 226 
where they learnt to alternate entry into the left and right arms of the maze. Each training day 227 
involved 10 trials, including 5 ‘forced’ and 5 ‘choice’ runs. During the ‘forced’ run, one arm 228 
of the maze was closed using a removable divider and the reward stimulus was placed in the 229 
open arm (Figure 1C). The divider position was randomly alternated between the left and 230 
right arms of the maze for each forced run. During the ‘choice’ run, the divider was removed 231 
and the reward stimulus was placed in the newly opened arm (Figure 1C). Training was 232 
considered successful when control animals achieved greater than 80% correct entry (Deacon 233 
and Rawlins, 2006). The same alternation methods were utilised on the test day, with a total 234 
of 10 trials (5 forced and 5 choice runs) per rat. There was a 30 second delay between the 235 
forced and choice trials, and the total trial time was 3 minutes. A response was considered 236 
correct when the rat positioned its whole body in the correct arm (Deacon and Rawlins, 237 
2006). Trials were excluded if the rat did not leave the start arm, jumped out of the maze or if 238 
the retention interval exceeded 45 seconds, as the duration of the interval between the forced 239 
and choice runs can impact cognitive performance (Freudenberg et al., 2013; Sharma et al., 240 
2014; Deacon and Rawlins, 2006).  241 
 242 
2.5 Post-Mortem Adiposity Measurement 243 
After six weeks, animals were fasted overnight and euthanized via CO2 asphyxiation. 244 
Subcutaneous inguinal, intra-abdominal perirenal and periovary white fat pads, and sub-245 
scapula brown fat pads were individually dissected and weighed.   246 
 247 
2.6 Statistical Analysis 248 
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Statistical analysis was performed using SPSS (version 21, SPSS, Chicago, IL, USA). Data 249 
were examined using Shapiro-Wilk tests for normality. Outliers ± 2 SD from the mean were 250 
removed, as previously published (Osborne et al., 2017). Two-way repeated ANOVAs 251 
(TREATMENT x TIME as repeated measures) were used to analyse cumulative weight gain, 252 
food and water intake, and glucose tolerance data. One-way ANOVAs were used to 253 
determine the effect of treatment on feeding efficiency, glucose AUC, voluntary locomotor 254 
activity (total distance travelled and velocity), NOR performance (discrimination ratio and 255 
total interaction time) and fat pad (inguinal, perirenal, periovary and sub-scapula) masses, 256 
followed by Tukey HSD and Dunnett-T tests for multiple comparisons (two-tailed). T-Maze 257 
data remained non-normally distributed despite log transformations, therefore, data were 258 
analysed using non-parametric Kruskall-Wallis followed by Mann-Whitney U tests for 259 
multiple comparisons. Comparisons included examination of changes in treatment groups 260 
compared to controls and differences between antipsychotic drug vs antipsychotic drug + 261 
liraglutide co-treatment groups. Correlations were identified using Pearson’s correlation tests. 262 
Significance was accepted at p<0.05.  263 
 264 
3. Results 265 
3.1 Body weight, food and water intake 266 
A two-way repeated ANOVA (TREATMENT x TIME) of cumulative body weight gain 267 
revealed a significant effect of treatment (F5,61 = 13.866, p<0.001) and time (F5,57 = 42.056, 268 
p<0.001), and a significant interaction between the two factors (F25,213 = 2.045, p<0.01). 269 
Compared to controls, olanzapine significantly increased body weight (weeks 1-6), while 270 
liraglutide co-treatment prevented this weight gain, with significantly decreased cumulative 271 
weight gain in the olanzapine + liraglutide group compared to the olanzapine treatment group 272 
(p<0.01 and p<0.001 throughout weeks 1-6) (Figure 2A). Liraglutide significantly decreased 273 
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body weight compared to the controls (p<0.05 and p<0.01 throughout weeks 1-4 and 6) 274 
(Figure 2A). As expected, clozapine did not alter body weight compared to the controls; 275 
however, clozapine + liraglutide co-treatment significantly decreased cumulative body weight 276 
during weeks 1 - 4 compared to the clozapine treatment group (Figure 2A). There was no 277 
significant effect of treatment on cumulative food intake, only an effect of time (p<0.001) 278 
(Figure 2B), and no alterations in cumulative water intake (Figure 2C). 279 
 280 
3.2 Adiposity 281 
There was a significant effect of treatment on subcutaneous inguinal (F5,65 = 6.317, p<0.001), 282 
intra-abdominal perirenal (F5,64 = 14.229, p<0.001), periovary (F5,66 = 12.835, p<0.001) and 283 
total white fat mass (F5,65 = 13.854, p<0.001) (Table 1). Compared to controls, liraglutide 284 
significantly reduced inguinal and perirenal (both p<0.05), periovary and total white fat mass 285 
(both p<0.01) (Table 1). Olanzapine significantly increased total white fat mass (p<0.01), 286 
including intra-abdominal peri-ovarian fat (p<0.05), while olanzapine + liraglutide co-287 
treatment prevented this hyperadiposity, with significantly less inguinal (p<0.05), perirenal, 288 
periovarian (p<0.001) and therefore total fat mass (p<0.01) compared to the olanzapine group 289 
(Table 1). Clozapine did not alter fat mass; however, clozapine + liraglutide treatment 290 
reduced intra-abomdinal fat (perirenal and periovary) and total fat mass compared to controls 291 
(all p<0.01) and clozapine treatment alone (p<0.001, p<0.05 and p<0.01, respectively) (Table 292 
1).  293 
 294 
3.3 Oral Glucose Tolerance Test 295 
There was a significant effect of treatment (F5,55 = 15.766, p<0.001) and time (p<0.001) on 296 
oral glucose tolerance test data, but no significant interaction between the two factors (F30,202 297 
= 1.392, p>0.05) (Figure 3A). Clozapine-treated rats had significantly higher fasting blood 298 
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glucose levels (baseline, time 0) compared to controls (p<0.05), while the clozapine + 299 
liraglutide group had significantly lower, control-like fasting blood glucose levels (p<0.001) 300 
(Figure 3A). Hyperglycaemia was evident in the clozapine group throughout the test, a result 301 
that was echoed in the glucose area under the curve data (p<0.05 vs controls, Figure 3B), and 302 
failed to reach control levels even after 180 minutes (p<0.05 vs controls, Figure 3A). On the 303 
contrary, liraglutide co-treatment prevented the hyperglycaemia caused by clozapine 304 
(p<0.001 cloz+lira vs cloz, Figure 3B) and control levels were reached by the end of the test 305 
(Figure 3A). Liraglutide treatment significantly decreased the glucose area under the curve 306 
(p<0.001 vs controls) (Figure 3B); however, this result was caused by a decrease in blood 307 
glucose levels during 60, 90 and 120 minutes test intervals and glycaemic balance was 308 
restored by 150 and 180 minutes (Figure 3A). Olanzapine and olanzapine + liraglutide co-309 
treatment groups did not differ to the controls throughout the test (Figure 3). 310 
 311 
3.4 Voluntary Locomotor Activity  312 
Olanzapine significantly reduced total distance travelled compared to the controls (p<0.001) 313 
(Figure 4). Liraglutide co-treatment with olanzapine significantly increased distance travelled 314 
compared to the olanzapine group (+75%, p<0.05); however, the distance in the co-treatment 315 
group was still significantly lower than the controls (p<0.001) (Figure 4A). A similar trend 316 
was observed in the velocity data, where olanzapine significantly reduced velocity compared 317 
to controls (p<0.001), and liraglutide co-treatment was able to improve velocity compared to 318 
the olanzapine group (p<0.05), but this improvement did not reach control levels (Figure 4B). 319 
Clozapine treatment did not significantly alter distance travelled or velocity compared to the 320 
controls; however, clozapine + liraglutide co-treatment significantly reduced these parameters 321 
compared to the controls (p<0.01) (Figure 4A and 4B). Interestingly, the liraglutide treatment 322 
group also exhibited reduced distance travelled and velocity compared to the controls 323 
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(p<0.05) (Figure 4). The distance travelled each hour over a 24-hour period is presented in 324 
Figures 4C and 4D). 325 
 326 
3.5 Novel Object Recognition Test 327 
There was a significant effect of treatment on the mean discrimination ratio (F5,66 = 13.95, 328 
p<0.001) (Figure 5A), with a reduction in the olanzapine and clozapine groups (both p<0.001 329 
vs controls), demonstrating reduced recognition memory in these rats. Interestingly, 330 
liraglutide co-treatment with olanzapine and clozapine prevented these deficits in recognition 331 
memory, restoring the discrimination ratio to control levels (both p>0.05 vs controls) and 332 
significantly improving the discrimination ratio compared to APD treatment alone (both 333 
p<0.001). Olanzapine and clozapine did not significantly impact total exploration time 334 
(p>0.05) (Figure 5B). In addition, there was a significant negative correlation between mean 335 
discrimination ratio and total white fat mass (g) (r=-0.43, p<0.001) (Figure 5C). 336 
 337 
3.6 Rewarded T-maze Alternation Test 338 
Olanzapine significantly reduced the mean percentage of correct entries in the rewarded T-339 
maze alternation test compared to the controls (p<0.05), indicating that olanzapine-treated 340 
rats had impaired aspects of working memory. Performance by the olanzapine + liraglutide 341 
co-treatment group did not differ to the controls (p>0.05) (Figure 6). Although olanzapine + 342 
liraglutide co-treatment improved the mean percentage of correct entries by 17%, this did not 343 
reach significance compared to the olanzapine group (Figure 6). There were no significant 344 
treatment effects on mean percentage of correct entries in the remaining groups.  345 
 346 
4. Discussion 347 
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The results of the present study show that liraglutide can prevent the obesity side-effects of 348 
olanzapine and the chronic hyperglycaemia side-effects of clozapine when administered from 349 
the start of treatment. A recent randomised clinical trial of schizophrenia patients treated with 350 
either olanzapine (n=15) or clozapine (n=32), who were obese (average patient body mass 351 
index of 33) and pre-diabetic found that liraglutide was able to treat already established 352 
obesity in these patients (causing an average weight loss of -5.6kg) and improved glycaemic 353 
balance by 23% (Larsen et al., 2017). On the other hand, administration of the long acting 354 
GLP-1R agonist exenatide (once-weekly) had no effect on body weight in obese 355 
schizophrenia patients (Ishøy et al., 2017b). The finding that a liraglutide intervention was 356 
able to treat the weight gain and glucose intolerance side-effects of olanzapine was first 357 
shown in rodents (Lykkegaard et al., 2008) and in a later case study (Ishøy et al., 2013); 358 
however, no studies had examined whether liraglutide could prevent the onset of metabolic 359 
side-effects when administered from the start of treatment. Therefore, the results of our study 360 
show promise for improved treatment of patients initiating APD treatment who are at an 361 
elevated risk of suffering metabolic side-effects. 362 
 363 
Liraglutide induces weight loss, in-part, by reducing appetite and inhibitory effects on the 364 
reward aspects of feeding behaviour (Holst, 2007; Pi-Sunyer et al., 2015); however, we did 365 
not observe significant changes in food intake in treated rats suggesting that body weight 366 
alterations were not due to hypophagia and reduced energy intake. Our previous studies 367 
showed that olanzapine dramatically increased body weight but with modest increases in food 368 
intake (Weston-Green et al., 2011; Weston-Green et al., 2012), demonstrating that appetite 369 
did not fully account for the body weight increases. On the contrary, food intake has been 370 
found to contribute to olanzapine-induced weight gain in a rat study using a different 371 
treatment regime (Davoodi et al., 2009). We also examined voluntary locomotor activity as 372 
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reduced motivation towards exercise has been reported in people with schizophrenia 373 
prescribed olanzapine and clozapine (Archie et al., 2003; Beebe et al., 2011) and GLP-1R 374 
signalling influences mesolimbic reward and motivation pathways in the brain (Richard et al., 375 
2015). Liraglutide co-treatment increased voluntary locomotor activity by 75% compared to 376 
the olanzapine group; however, control levels were not restored. Therefore, when considering 377 
the basic energy balance equation (energy intake versus energy expenditure) these results 378 
suggest that factors other than food intake and exercise are involved in the weight gain 379 
caused by olanzapine in the present study, as well as the ability of liraglutide to prevent it. 380 
However, pair feeding studies would be required to confirm. Weight changes were associated 381 
with increased adiposity in the present study. Indeed, olanzapine promotes lipid accumulation 382 
by upregulating the lipogenesis pathway (Albaugh et al., 2010), while liraglutide reduces 383 
adipogenic and lipolytic markers (El Bekay et al., 2016). Liraglutide also reduced adiposity 384 
below control levels when combined with clozapine, but food intake and locomotor activity 385 
were unaltered in the clozapine groups. This is consistent with a previous report that 386 
liraglutide lowers the respiratory quotient in obese people, indicating a switch towards 387 
increased fat oxidation (van Can et al., 2014). Future investigation into treatment effects on 388 
markers of lipid oxidation is warranted. 389 
 390 
In the present study, cumulative body weight gain significantly increased with olanzapine, 391 
but not clozapine treatment compared to the controls, coinciding with evidence over the past 392 
14 years that rodents are resistant to clozapine-induced weight gain (Choi et al., 2007; Cooper 393 
et al., 2008; Albaugh et al., 2006; Pouzet et al., 2003; Weston-Green et al., 2011). 394 
Nonetheless, clozapine-induced hyperglycaemia side-effects can be modelled in rodents 395 
(Tulipano et al., 2007); a result that was replicated in this study. Similar to our study, the 396 
obesity and diabetes side-effects of olanzapine and clozapine can also manifest 397 
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simultaneously or independently in patients (Stahl et al., 2009). Clozapine caused fasting 398 
hyperglycaemia and impaired glucose clearance during the OGTT, which is consistent with 399 
clinical (Ishøy et al., 2013; Hägg et al., 1998) and animal studies (Boyda et al., 2010). Blood 400 
glucose levels in the clozapine group did not return to a homeostatic level by the end of the 401 
OGTT, indicative of poor insulin response to rising blood glucose levels and suggests the 402 
presence of a diabetic phenotype in these rats. Importantly, liraglutide co-treatment prevented 403 
these effects. Liraglutide alone induced lower weight gain than the controls, but rats in this 404 
group were normo-glycaemic, even following an overnight fast. This result is consistent with 405 
clinical studies reporting that liraglutide causes weight loss and has a low hypoglycemic risk 406 
(Feng et al., 2015; Lind et al., 2015). While clozapine increases glucagon secretion and 407 
stimulates hepatic glucose output (Smith et al., 2008), liraglutide activates GLP-1 receptors 408 
expressed on pancreatic α cells to inhibit the release of glucagon and suppress hepatic 409 
glucose output in a glucose-dependent manner (Steinert et al., 2016). In addition, GLP-1 410 
delays gastric emptying (van Can et al., 2014), stimulates pancreatic beta cell proliferation 411 
and improves glucose sensitivity in these cells (Tamura et al., 2015). Furthermore, GLP-1 412 
receptors are expressed in glucoreceptive regions of the brain that control blood glucose and 413 
food intake, including the caudal brainstem and hypothalamus (Alvarez et al., 2005), that 414 
may be altered by clozapine and liraglutide treatment.  415 
 416 
This study is novel in its finding that liraglutide can prevent deficits in cognition that were 417 
associated with olanzapine and clozapine, when administered from the start of treatment. 418 
Olanzapine and clozapine impaired performance in the NOR test, while liraglutide co-419 
treatment prevented these behavioural deficits. Olanzapine also caused deficits in T-Maze 420 
behaviour that were not evident in the olanzapine+liraglutide co-treatment group compared to 421 
controls. Liraglutide produced no changes in any of the behaviours examined when 422 
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administered alone, but was able to prevent APD-induced cognitive deficits with results 423 
demonstrating control-like levels of performance in the co-treatment groups. The inability to 424 
discriminate familiar compared to novel objects demonstrates a deficit in recognition memory 425 
and learning (Bevins and Besheer, 2006), while impaired T-maze performance suggests 426 
impaired working memory (Deacon and Rawlins, 2006), both of which are prominent 427 
features of cognitive impairment in schizophrenia (McGuire et al., 2013). A recent clinical 428 
study reported no cognitive benefits of long-acting exenatide (once-weekly) in patients with a 429 
criteria of obesity, diagnosed schizophrenia spectrum disorder and a minimum of 3 months of 430 
APD treatment (including typical 1st and atypical 2nd generation drugs as well as 431 
polypharmacy) (Ishøy et al., 2017a). Several explanations for the confounding results may 432 
include 1) a difference in dosage between the studies, 2) findings in healthy rodents may not 433 
translate to humans with schizophrenia disorders, or 3) possible pharmacological differences 434 
between long-acting exenatide and liraglutide. On the latter two points, the same group also 435 
reported no effects of long-acting exenatide on body weight in a similar clinical study (Ishøy 436 
et al., 2017b); however, liraglutide induced persistent weight loss and metabolic benefits in 437 
an earlier case study of an obese patient with schizophrenia treated with clozapine (Ishøy et 438 
al., 2013), a result translated from rats (Lykkegaard et al., 2008). Another explanation may be 439 
that our prevention study employed liraglutide co-treatment from the start of APD treatment. 440 
Studies show that liraglutide can cross the blood brain barrier, promote neuronal stem cell 441 
proliferation and neurogenesis, and provides neuroprotective effects (Hunter and Holscher, 442 
2012), including preserved synaptic number and function, and reduced neuroinflammation 443 
(McClean and Hölscher, 2014; McClean et al., 2011). In other studies, liraglutide normalised 444 
object recognition in a mouse model of Alzheimer’s disease after 8 months of treatment 445 
(McClean et al., 2015), exenatide and exendin-4 improved memory and spatial learning in the 446 
Morris Water Maze in models of Alzheimer’s disease and cognitive deficits induced by 447 
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impaired central insulin signalling (Bomba et al., 2013; Chen et al., 2012), and recognition 448 
memory was improved by liraglutide (0.2mg/kg, b.i.d.) in mice following a 20-week high fat 449 
diet (Porter et al., 2010). On the other hand, APDs olanzapine and risperidone exacerbated 450 
deficits in spatial working memory and attention during the Oculomotor Delayed Response 451 
task (Reilly et al., 2007) and decreased dorsolateral prefrontal cortex activation during motor 452 
learning tasks (Keedy et al., 2015) in previously APD-naïve schizophrenia patients after 4-6 453 
weeks of treatment. In rodents, olanzapine impaired working memory during Y-Maze and 454 
Eight-Arm Radial Maze tests (Castro et al., 2007; Levin et al., 2005; Ortega-Alvaro et al., 455 
2006), and reduced memory acquisition and retrieval in mice during the modified Elevated 456 
Plus Maze task (Mutlu et al., 2011). Clinically, APDs can cause varying degrees of sedation 457 
(Leucht et al., 2009) and it is possible that sedation impacted the cognitive data. However, in 458 
the present study neither APD affected overall exploration time in the NOR test and 459 
clozapine treated animals displayed impaired NOR test performance without exhibiting 460 
hypolocomotor activity. In addition, treatment effects on reward and motivation may have 461 
also played a role in cognitive test performance in the present study. 462 
 463 
The underlying mechanisms by which GLP-1 analogues exert beneficial effects on cognition 464 
in the brain remain unclear. Interestingly, studies have shown that olanzapine decreases 465 
hippocampal volume (Barr et al., 2013) and lowers hippocampal connectivity (i.e. reduces 466 
inhibitory terminal immunodensity) in rats (Ramos-Miguel et al., 2015). On the other hand, 467 
neuronal GLP-1 has growth characteristics similar to insulin-like growth factor (see review 468 
by Bassil et al., 2014), which may enable it to stimulate neurogenesis and hippocampal 469 
plasticity to improve cognition. GLP-1 is also a neurotransmitter (Larsen and Holst, 2005), 470 
with GLP-1Rs expressed in regions of the brain that are both implicated in cognition and 471 
house major neurotransmitter pathways (dopamine, acetylcholine and serotonin) (i.e. the 472 
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frontal and temporal cortices, nucleus basalis Meynert, hippocampus, nucleus accumbens, 473 
amygdala, ventral tegmental area, substantia nigra, raphe nuclei and locus ceruleus) (Larsen 474 
and Holst, 2005; Merchenthaler et al., 1999). This anatomical arrangement suggests that the 475 
GLP-1 system interacts with other neurochemical systems in the brain. GLP-1 neurons of the 476 
NTS project to the nucleus accumbens and amygdala via the ventral tegmental area (i.e. the 477 
dopaminergic mesolimbic pathway) to alter the reward aspects of food intake (Alhadeff et al., 478 
2012). In addition, central injection of exendin-4 increases dopamine turnover (upregulates 479 
levels of dopamine metabolites 3,4-dihydroxyphenylacetic acid and homovanillic acid) in the 480 
amygdala and this effect is abolished by D2 receptor antagonism (Anderberg et al., 2014), 481 
demonstrating an interaction between GLP-1 and D2 receptor signalling in a region of the 482 
brain implicated in reward, emotional processing and learning and memory. Olanzapine and 483 
clozapine are potent D2 receptor antagonists (McCormick et al., 2010), therefore, a GLP-484 
1/D2 receptor interaction may be a potential mechanism by which liraglutide exerts its 485 
beneficial effects on cognition. The anti-cholinergic properties of olanzapine and clozapine 486 
may also contribute to cognitive dysfunction (McGurk et al., 2004), while exendin-4 487 
upregulates choline acetyltransferase in-vitro and restores cholinergic neuron activity in the 488 
basal forebrain (involved in episodic memory retrieval in humans (Fujii et al., 2002)), in a 489 
rodent neurodegeneration model (Perry et al., 2002). Together with the behavioral findings of 490 
the present study, evidence suggests that liraglutide may restore control-like levels to 491 
neurotransmitter imbalances caused by APDs to improve cognition. However, liraglutide 492 
alone did not increase cognitive performance above control levels. Therefore, a second 493 
possibility is that the cognitive benefits of liraglutide were related to metabolic improvement. 494 
We identified a correlation between NOR test performance and adiposity and have previously 495 
shown that schizophrenia patients with comorbid diabetes had worsened cognitive 496 
performance than patients without diabetes (Han et al., 2013); a result echoed in 497 
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schizophrenia patients with metabolic syndrome (Lindenmayer et al., 2012). Therefore, 498 
further investigation into key neurotransmitter systems and the role of metabolic dysfunction 499 
in the cognitive benefits of liralgutide treatment observed in the present study are required.  500 
 501 
In conclusion, liraglutide co-treatment from the start of APD administration prevented 502 
metabolic side-effects and cognitive deficits in rats. A limitation of this study is the use of 503 
healthy rodents and future studies may benefit from examining the efficacy of liraglutide in a 504 
schizophrenia pathology model prior to translation into humans. Overall, the results of this 505 
study provide evidence supporting the use of liraglutide as an adjunct therapy to improve the 506 
treatment of people with schizophrenia. This approach may particularly benefit patients 507 
already at a high risk of experiencing metabolic side-effects, including those commencing 508 
APD treatment with pre-existing T2DM and/or obesity, patients re-commencing APD 509 
treatment following non-compliance due to metabolic side-effects, or patients switching 510 
APDs in the presence of existing metabolic side-effects.  511 
  512 
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9. Table and Figure Legends: 807 
Figure 1 (A) The experimental timeline, (B) a schematic representation of the Novel Object 808 
Recognition (NOR) test used to assess recognition memory, and (C) a schematic 809 
representation of the rewarded T-maze alternation test used to assess working memory.  810 
 811 
Table 1 Fat pad mass (g) of female Sprague Dawley rats following 6-weeks treatment with 812 
liraglutide (0.2mg/kg, Lira), olanzapine (2mg/kg, Olan), olanzapine+liraglutide co-treatment 813 
(Olan + Lira), clozapine (12mg/kg, Cloz), clozapine+liraglutide co-treatment (Cloz + Lira) or 814 
vehicle (Control). Data presented as mean ± S.E.M. (n=9-12/group). *p<0.05 vs. Control, 815 
**p<0.01 vs. Control, #p<0.05 vs. Olan, ##p<0.01 vs. Olan, ###p<0.001 vs. Olan, ^p<0.05 vs. 816 
Cloz, ^^p<0.01 vs. Cloz, ^^^p<0.001 vs. Cloz. BAT: Brown adipose tissue. 817 
 818 
Figure 2 Cumulative (A) body weight gain (g), (B) food intake (g) and (C) water intake (g) 819 
in female Sprague Dawley rats following 6-weeks treatment with liraglutide (0.2mg/kg, Lira), 820 
olanzapine (2mg/kg, Olan), olanzapine+liraglutide co-treatment (Olan + Lira), clozapine 821 
(12mg/kg, Cloz), clozapine+liraglutide co-treatment (Cloz + Lira) or vehicle (Control). Data 822 
presented as mean ± S.E.M. (n=10-12/group). *p<0.05 vs. Control, **p<0.01 vs. Control, 823 
***p<0.001 vs. Control, ##p<0.01 vs. Olan, ###p<0.001 vs. Olan, ^p<0.05 vs. Cloz, ^^p<0.01 824 
vs. Cloz. 825 
 826 
Figure 3 (A) Blood glucose concentration (mmol/L) and (B) glucose Area Under the Curve 827 
during an Oral Glucose Tolerance Test in female Sprague Dawley rats following 2-weeks 828 
treatment with liraglutide (0.2mg/kg, Lira), olanzapine (2mg/kg, Olan), 829 
olanzapine+liraglutide co-treatment (Olan + Lira), clozapine (12mg/kg, Cloz), 830 
clozapine+liraglutide co-treatment (Cloz + Lira) or vehicle (Control). Data presented as mean 831 
 
30 
 
± S.E.M. (n=10-12/group). *p<0.05 vs. Control, **p<0.01 vs. Control, ***p<0.001 vs. 832 
Control, ^^p<0.01 vs. Cloz, ^^^p<0.001 vs. Cloz. 833 
 834 
Figure 4 Voluntary locomotor activity showing (A) Total distance travelled (m), (B) total 835 
velocity (m/min) and (C-D) hourly distance travelled by female Sprague Dawley rats over 24 836 
hours following 6-weeks of treatment with liraglutide (0.2mg/kg, Lira), olanzapine (2mg/kg, 837 
Olan), olanzapine+liraglutide co-treatment (Olan + Lira), clozapine (12mg/kg, Cloz), 838 
clozapine+liraglutide co-treatment (Cloz + Lira) or vehicle (Control). Olanzapine and 839 
clozapine treatments were administered at 6, 14 and 22 h, while liraglutide was administered 840 
at 6 and 22 h. Data presented as mean ± S.E.M. (n=10-12/group). *p<0.05 vs. Control, 841 
**p<0.01 vs. Control, ***p<0.001 vs. Control, #p<0.05 vs. Olan. 842 
 843 
 Figure 5 (A) Discrimination ratio and (B) total interaction time (s) during a Novel Object 844 
Recognition (NOR) test in female Sprague Dawley rats following treatment with liraglutide 845 
(0.2mg/kg, Lira), olanzapine (2mg/kg, Olan), olanzapine+liraglutide co-treatment (Olan + 846 
Lira), clozapine (12mg/kg, Cloz), clozapine+liraglutide co-treatment (Cloz + Lira) or vehicle 847 
(Control). (C) Correlation between Discrimination Ratio and total white fat mass (g). Data 848 
presented as mean ± S.E.M. (n=11-12/group). ***p<0.001 vs. Control, ###p<0.001 vs. Olan, 849 
^^^p<0.001 vs. Cloz. 850 
 851 
Figure 6 Percentage of correct entries in the T-Maze test by female Sprague Dawley rats 852 
following 6-weeks treatment with liraglutide (0.2mg/kg, Lira), olanzapine (2mg/kg, Olan), 853 
olanzapine+liraglutide co-treatment (Olan + Lira), clozapine (12mg/kg, Cloz), 854 
clozapine+liraglutide co-treatment (Cloz + Lira) or vehicle (Control). Data presented as mean 855 
± S.E.M. (n=11-12/group). *p<0.05 vs. Control. 856 
Table 1 857 
  
Control Lira Olan Olan + Lira Cloz Cloz + Lira 
Fat Pad Mass (g) 
      
 
Inguinal 
(subcutaneous) 
2.2 ± 0.3 1.3 ± 0.1* 2.8 ± 0.3 1.8 ± 0.2
# 2.3 ± 0.2 1.5 ± 0.1 
 
Perirenal (intra-
abdominal) 
3.0 ± 0.4 1.2 ± 0.1* 4.1 ± 0.4 1.8 ± 0.3
### 3.5 ± 0.4 1.3 ± 0.1**̂ ^^ 
 
Periovary (intra-
abdominal) 
3.7 ± 0.5 1.6 ± 0.3** 5.4 ± 0.6* 2.3 ± 0.4
### 3.7 ± 0.4 1.8 ± 0.2**̂  
 
Subscapula (BAT) 0.3 ± 0.0 0.2 ± 0.0 0.3 ± 0.0 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0 
Total White Fat 8.3 ± 1.1 4.6 ± 0.6** 12.3 ± 1.0** 6.0 ± 0.8
### 9.5 ± 0.8 4.6 ± 0.4**̂ ^ 
* p < 0.05, ** p < 0.01, *** p < 0.001  vs. control,  
# p < 0.05, ## p < 0.01, ### p < 0.01 vs. olanzapine,  
^ p < 0.05, ^^ p < 0.01, ^^^ p < 0.001 vs. clozapine. 
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